Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
-- Transaction continues to advance Mallinckrodt's strategic focus on branded biopharmaceuticals by monetizing a non-core business ---- H.I.G. Capital to support BioVectra leadership and its attractive growth plan --
STAINES-UPON-THAMES,?United Kingdom?and?MIAMI,?Sept. 10, 2019?/PRNewswire/ --?Mallinckrodt plc?(NYSE: MNK), a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary?BioVectra Inc.?to an affiliate of?H.I.G. Capital, a leading global private equity investment firm, for approximately?$250 million, including fixed consideration of?$175 million, comprised of an upfront payment of?$135 million?and a long-term note for?$40 million, and contingent payments of up to?$75 million, enabling?Mallinckrodt?to capture future BioVectra growth potential.
BioVectra is a contract development and manufacturing organization (CDMO) whose global client base includes many of the top biopharmaceutical companies in the world.?The company has a unique mix of capabilities, with core growth engines in complex chemistry, biologics and drug development. BioVectra will continue to supply an active pharmaceutical ingredient supporting?Mallinckrodt's?specialty brands business under a long-term arrangement. The transaction is anticipated to include all of BioVectra's sites in?Prince Edward Island?and?Nova Scotia, Canada, as well as its employee base.
"This transaction continues to advance?Mallinckrodt's?strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business," said?Mark Trudeau, President and Chief Executive Officer of?Mallinckrodt. "While we recognize the longer-term growth potential for BioVectra, we believe that the structure of this deal enables us to participate in the future success of the business, and therefore we see this sale as the best option for both?Mallinckrodt?and BioVectra moving forward."
"We are excited to support BioVectra's exceptional leadership and highly dedicated employees," said?Mike Gallagher, Managing Director at?H.I.G. Capital. "BioVectra demonstrates a tremendous ability to generate robust organic growth and utilizes a broad set of technical capabilities to deliver outstanding service and quality. They are completing major capital expenditure programs to significantly expand capacity and the company is well positioned to capitalize on growing demand for their services."
The transaction is expected to close in the fourth quarter of 2019,?subject to customary?closing conditions. It is not anticipated that the sale will have any material tax impact to?Mallinckrodt. The company intends to use the proceeds from this divestiture consistent with its previously disclosed capital allocation priorities.
Goldman Sachs & Co. LLC?served as financial advisor and?Latham & Watkins LLP?served as legal advisor to?Mallinckrodt?in connection with the transaction.
Wells Fargo Securities LLC?served as financial advisor and?McDermott Will & Emery LLP?served as legal advisor to?H.I.G. Capital.
About BioVectra
BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients (APIs). An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:
- cGMP microbial fermentation
- Complex chemistry ? high potency APIs
- Biologics
- Formulation development
- H.I.G.'s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.'s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC,?WhiteHorse Finance.
- H.I.G.'s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
?View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-agrees-to-sell-biovectra-inc-to-hig-capital-for-250-million-300914526.html
SOURCE?Mallinckrodt plc